Conquering oncogenic KRAS and its bypass mechanisms

Related Experiment Video

Updated: Sep 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Pingping Hou1,2,3,4, Y Alan Wang5

  • 1Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA.

Theranostics
|August 15, 2022
PubMed

Insights

Targeting KRAS signaling in cancer shows promise, but resistance mechanisms limit effectiveness. Understanding these bypass pathways is key to developing effective combination therapies for KRAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Aberrant KRAS signaling is a hallmark of many cancers, driving the development of targeted therapies.
  • Novel small molecule drugs targeting KRAS and its effectors show preclinical and clinical promise.
  • Cancer's inherent genetic and biological plasticity leads to resistance mechanisms against targeted therapies.

Purpose of the Study:

  • To review the mechanisms of resistance to KRAS-targeted therapies.
  • To highlight the importance of understanding resistance for improving clinical outcomes.
  • To inform the development of combination strategies against KRAS-driven cancers.

Main Methods:

  • Literature review of preclinical and clinical studies on KRAS-targeted therapies.
  • Analysis of identified resistance mechanisms in various cancer types.
  • Synthesis of knowledge to propose combination strategies.

Main Results:

  • KRAS-targeted drugs demonstrate significant activity but are often limited by acquired resistance.
  • Diverse resistance mechanisms, including bypass signaling pathways, are frequently observed.
  • Understanding these resistance mechanisms is crucial for overcoming therapeutic limitations.

Conclusions:

  • Targeted inhibition of KRAS is a viable strategy, but resistance remains a significant challenge.
  • Combination therapies that address both KRAS dependency and bypass mechanisms are needed.
  • Further research into resistance pathways will guide the next generation of cancer treatments.
Keywords:
KRASMEKRAFcancertargeted therapy resistance

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K